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Abstract
Rationale and aims: Lung health of people with cystic fibrosis (PwCF) can be pre-
served by daily use of inhaled therapy. Adherence to inhaled therapy, therefore, pro-
vides an important process measure to understand the success of care and can be
used as a quality indicator. Defining adherence is problematic, however, since the
number of prescribed treatments varies considerably between PwCF. The problem is
less pronounced among those with Pseudomonas aeruginosa (PA), for whom at least
three daily doses of nebulized therapy should be prescribed and who thus constitute
a more homogeneous group. The UK CF Registry provides routine data on PA status,
but data are only available 12 months after collection. In this study, we aim to pro-
spectively identify contemporary PA status from historic registry data.
Method: UK CF Registry data from 2011 to 2015 for PwCF aged ≥16 was used to
determine a pragmatic prediction rule for identifying contemporary PA status using
historic registry data. Accuracy of three different prediction rules was assessed using
the positive predictive value (PPV). The number and proportion of adults predicted to
have PA infection were determined overall and per center for the selected prediction
rule. Known characteristics linked to PA status were explored to ensure the robust-
ness of the prediction rule.
Results: Having CF Registry defined chronic PA status in the two previous years is
the selected definition to predict a patient will have PA infection within the current
year (population-level PPV = 96%-97%, centre level PPV = 85%-100%). This
approach provides a subset of data between 1852 and 1872 patients overall and a
range of 8 to 279 patients per center.
Conclusion: Historic registry data can be used to contemporaneously identify a sub-
group of patients with chronic PA. Since this patient group has a narrower treatment
schedule, this can facilitate a better benchmarking of adherence across centers.
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1 | INTRODUCTION
Cystic fibrosis (CF) is an archetypal long-term condition for which
there is as yet no cure, but regular use of preventative therapies can
improve health outcomes by reducing the frequency of exacerbations
and attenuating lung function (forced expiratory volume in 1 second,
FEV1) decline.
1 However, adherence to preventative inhaled treat-
ments in CF is generally low (30%-35%) and low adherence is associ-
ated with worse health outcomes.2,3 Measuring adherence at an
individual level is important for treatment planning and diagnosis in
the event of declining lung health. Measuring system-level adherence
is also important because benchmarking across centers within a com-
munity of practice can provide a basis to share strategies for improve-
ment. Various quality improvement (QI) initiatives in CF have
transformed the delivery of healthcare, for example, streamlined
approaches to managing acute exacerbations and increased prescrip-
tion of efficacious preventative inhaled therapies.4 Improving adher-
ence to inhaled therapies is, therefore, a logically important target for
QI projects. QI projects focused on adherence can compare between
and within centers, therefore providing an understanding of the varia-
tion of care across UK centers.
System-level indicators are most useful when they are indepen-
dent of local constraints on data capture since the factors that impact
quality of care may also impact data capture. Data-logging nebulizers
available in CF can objectively and accurately record each dose of
inhaled treatments taken by patients every day.5 However, accurate
prescriptions data may be unavailable, which impacts the ability to cal-
culate percentage adherence. Yet adherence among people with CF is
typically presented as a percentage because the required number of
treatment doses will vary according to disease severity. A person
without chronic PA and FEV1 80% may only require dornase alfa once
daily, whereas someone with chronic PA, FEV1 30% with large vol-
ume of sputum may require alternating antibiotics twice daily, dornase
alfa once daily, and hypertonic saline twice daily.
Identifying a subgroup of people with CF (PwCF) where the pre-
scription, and therefore denominator for adherence, can be implied
using routine data, despite local challenges in data capture, is an
important step toward providing adherence comparisons at the center
level. One option is to focus on those who have chronic P. aeruginosa
(PA) infection as consensus exists on the treatment these patients
should receive. All major CF guidelines recommend the use of long-
term inhaled antibiotics and mucolytics for people with chronic PA
infection, and this provides a minimum denominator of three drugs
for those PwCF with chronic PA. Using registry data to identify
patients with chronic PA and designating that these patients should
receive at least three daily doses of inhaled drugs (denominator)
allows adherence data captured by CFHealthHub6 (which provides
numerator data) to calculate an adherence rate even when
prescription data are missing. Although these data will be less accu-
rate in centers without accurate prescription data, this method of cal-
culating adherence data does allow a standardized approach to be
used in a well-defined subset of PwCF allowing center benchmarking
that can start an informed exploration of practice.7
The aim of system-level indicators using routine data where pos-
sible allows all centers to be included within comparisons, even those
that do not have the resources to provide data consistently as the
identification of the subgroup with PA uses routine data from the CF
Registry. Published UK CF Registry provides historic data on PA status
1 year in arrears. As PA status may fluctuate over time, it is important
that the contemporary status is understood as accurately as possible
to identify the PA subgroup. Thus, the overarching aim of this paper is
to develop a rule to accurately predict which patients will have PA in
the current year on the basis of previous years' data collected rou-
tinely in the UK CF Registry. It is important to ensure that any predic-
tion rule has an appropriate compromise between sensitivity and
specificity to identify a sufficient number of people to allow center
comparisons. Thus, the analysis described in this paper sought to
determine the optimal rule for prospectively identifying patients who
have PA in the current year (trading off accuracy and number). In addi-
tion, we explored how other patient characteristics that might be
expected to be associated with PA status such as age were related to
the PA identifying strategies used.
2 | METHODS
Retrospective data were collected from the UK CF Registry database
for annual reviews between 2011 and 2015 from all UK CF centers.
National Health Service (NHS) research ethics approval was granted
for the use of UK CF Registry data (Huntingdon Research Ethics Com-
mittee 07/Q0104/2), and under these terms, the UK CF Trust
Steering Committee approved this study. The data received had
pseudo-anonymized patient and center details.
The following data were obtained from the registry:
• Demographics: CF center identifier, gender, age
• Body mass index (BMI) in kg/m2
• FEV1 during annual review (in % predicted, calculated with GLI
equations8)
• Indices of multiple deprivation (IMD) collected in each of the four
UK countries and adjusted to the equivalent English value9
• P. aeruginosa status: chronic (registry definition of three or more
positive samples in a 1-year period, regardless of the number of
samples sent), intermittent (one or two positive samples in a
1-year period), none (no positive samples identified in a 1-year
period)
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• Pancreatic status: pancreatic insufficient (those on pancreatic
replacement therapy [PERT]) or pancreatic sufficient (those not
on PERT)
• CF-related diabetes (CFRD): present or not present, as defined by
the UK CF Trust guideline10
• Annual total intravenous (IV) antibiotic use: total annual number
of home and hospital IV antibiotic days
• Lung transplant: year of transplant
All adults aged 16 years and above were included in the analyses,
with the exception of those undergoing lung transplantation who
were excluded from the year of transplant onwards.11
For this analysis, we compared the accuracy of three prediction
rules that have been selected from clinical knowledge of factors
affecting a patient's PA status, and that can be derived from routinely
collected data in the CF Registry:
1. Patients with three or more positive PA samples in the previous
year (these are classified as “chronic” according to the UK CF Reg-
istry guidance),
2. Patients with any positive PA samples in the previous year
(“chronic” as above plus patients with one or two PA samples that
are classified as “intermittent” according to the UK CF Registry
guidance),
3. Patients with any positive PA samples and/or at least 14 days of
IV antibiotics (home or hospital) in the previous year.
The rules aim to predict whether a patient will have any positive
PA samples within the current year (ie, been classified as “chronic” or
“intermittent” by the CF Registry).
The accuracy of the prediction rule was assessed using the posi-
tive predictive value (PPV) of the prediction against the outcome of
the patients having positive PA samples within the current year based
on past years' data. The definition producing the highest PPV
(or equivalently, the smallest proportion of patients misclassified as
having PA) was taken on to further analysis in which we assessed the
impact of increasing the number of years of past data to include in the
prediction rule. We calculated the PPV for one, two, three, and four
consecutive years' PA diagnosis in order to find the best compromise
between accuracy and number of patients included in the subgroup.
Once a final prediction rule had been selected, we used logistic
regression to assess the robustness of the prediction rule by calculat-
ing the PPV adjusted for other patient characteristics. The covariates
included in the model were as follows: age, pancreatic status, FEV1,
BMI, presence of CFRD, IMD, and IV days all as fixed effects, along
with center as a random effect. The functional form of continuous
covariates was assessed visually using lowess smoothing12 and using
fractional polynomials13; this is particularly important for age, since
the relationship has been shown to be nonlinear within younger
patients.14
As multiple years' data are available to make predictions, the
model was repeated with all data possible, allowing the consistency of
the covariates' effect on the prediction to be assessed. The discrimi-
nant ability of the model was quantified using the area under the
receiver-operator curve. Since most patients contributed to more than
1 year, the findings of separate predictive models were not combined.
Funnel plots15 were created to show the PPV by center and iden-
tify any outliers from the prediction rule, using both unadjusted and
adjusted PPV. No imputation was performed on missing data. All ana-
lyses were performed using R V3.4.116 and Stata V15.17
3 | RESULTS
The flowchart in Figure 1 shows the number of patients contributing
data to the UK CF Registry in each year. One of the 28 centers did
not contribute data to years 2012 and 2013, this center was excluded
from all center-level summaries. The characteristics for the population
of patients included in the final master dataset are shown in Table 1,
split by year.
F IGURE 1 Flowchart of patients
within the final dataset
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For each of the four time periods, 94% of patients with chronic
PA were found to have PA in the subsequent year. The other predic-
tion rules included a greater number of patients but a smaller propor-
tion with PA (range 79%-90%; Table 2).
Using the prediction rule of chronic PA status in previous years,
the optimum number of consecutive years' data to use was explored
and the results are shown in Table 3. As expected, the PPV increases
with extra years' data (range: 94%-98%), and Figure 2 shows this
against the number within the subset, which decreases as more years'
data are included. Taking the two together suggests the optimal
threshold for the prediction rule is to select those with two successive
years of a chronic PA status to predict the current years' status,
thereby allowing a sufficiently large sample to be used for future
research (average N = 1862) without appreciably reducing the confi-
dence in the accuracy of the diagnosis (average PPV = 96%). The con-
tingency table for the PPV calculations of this chosen prediction rule
for 2013 is shown in Table 4, and the contingency tables for 2014
and 2015 are in Table A1 and the resulting funnel plots in Figure A1.
TABLE 1 Year-by-year patient characteristics
2011 2012 2013 2014 2015
N = 4306 N = 4378 N = 4527 N = 4924 N = 5056
Age (years)
Mean (SD) 29.3 (10.1) 29.7 (10.3) 30.0 (10.4) 30.4 (10.6) 30.6 (10.7)
BMI (kg/m2)
Mean (SD) 22.6 (3.8) 22.5 (3.8) 22.6 (3.9) 22.7 (3.9) 22.9 (4.1)
Missing (%) 74 (2%) 136 (3%) 125 (3%) 111 (2%) 124 (2%)
CFRD N (%)
Yes 1271 (30%) 1342 (31%) 1421 (31%) 1601 (33%) 1676 (33%)
No 3035 (70%) 3036 (69%) 3106 (69%) 3323 (67%) 3380 (67%)
FEV1 (% predicted)
Mean (SD) 62.9 (23.6) 62.0 (23.9) 62.5 (23.8) 63.4 (23.9) 63.4 (23.8)
Missing (%) 110 (2%) 214 (5%) 180 (4%) 200 (4%) 208 (4%)
IV days
Mean (SD) 25.0 (36.6) 24.7 (38.1) 23.9 (35.8) 23.4 (37.0) 22.0 (35.3)
Missing (%) 58 (1%) 5 (<1%) 5 (<1%) 0 (0%) 0 (0%)
IMD
Mean (SD) 22.0 (15.7) 21.6 (15.4) 21.7 (15.4) 21.9 (15.6) 22.0 (15.6)
Quintile 1 – least deprived 764 (18%) 795 (18%) 827 (18%) 875 (18%) 898 (18%)
Quintile 2 828 (19%) 853 (19%) 880 (19%) 946 (19%) 981 (19%)
Quintile 3 851 (20%) 875 (20%) 894 (20%) 975 (20%) 999 (20%)
Quintile 4 810 (19%) 822 (19%) 850 (19%) 948 (19%) 956 (19%)
Quintile 5 – most deprived 749 (17%) 735 (17%) 765 (17%) 842 (17%) 879 (17%)
Missing (%) 304 (7%) 298 (7%) 311 (7%) 338 (7%) 343 (7%)
Sex N (%)
Female 1926 (45%) 1969 (45%) 2053 (45%) 2223 (45%) 2297 (46%)
Male 2380 (55%) 2409 (55%) 2474 (55%) 2701 (55%) 2759 (54%)
P. aeruginosa status N (%)
Chronic 2447 (57%) 2457 (56%) 2428 (54%) 2477 (50%) 2432 (48%)
Intermittent 532 (13%) 527 (12%) 605 (13%) 726 (15%) 709 (14%)
None 1327 (31%) 1394 (32%) 1494 (33%) 1721 (35%) 1915 (38%)
Pancreatic status N (%)
Insufficient 3508 (81%) 3574 (82%) 3682 (81%) 4008 (81%) 4107 (81%)
Sufficient 699 (16%) 727 (17%) 774 (17%) 869 (18%) 886 (18%)
Missing 99 (2%) 77 (2%) 71 (2%) 47 (1%) 63 (1%)
Abbreviations: BMI, body mass index; CFRD, cystic fibrosis related diabetes; FEV1, forced expiratory volume; IMD, indices of multiple deprivation; IV,
intravenous.
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3.1 | Center comparisons
The PPV was reasonably consistent across the 27 centers (range:
85%-100%). The number selected in the subgroup for each center had
a median of at least 49 (from 2013 prediction year) with a range from
8 to 279 (over all prediction years). More details are in Table A2.
3.2 | Predictive modeling
The final analyses sought to identify whether the PPV were associ-
ated with the patient's demographic and clinical features. These
analyses included patients that were recorded as having PA in two
successive years and were aged under 60. Patients over 60 are both
uncommon and also much more likely to be pancreatic sufficient than
other age groups, suggesting that they have a preponderance of less
severe phenotypes. Analyses were undertaken separately for patients
in 2013, 2014, and 2015 separately (Table 5).
The models for three different years showed no consistency
for significant predictors, and only age appeared more than once.
In all years, the predictive ability of the model was low with an
area under the curve of 0.66, 0.68, and 0.63, respectively,
suggesting a small influence of the variables to the prediction.
This suggests that the chosen rule of “chronic” PA for two
TABLE 2 PPV for three initial prediction rules
Prediction rule









Chronic PA status 94% (93%, 95%) 94% (93%, 95%) 94% (93%, 95%) 94% (94%, 95%)
Chronic or intermittent PA status 90% (89%, 91%) 90% (89%, 91%) 88% (87%, 89%) 87% (86%, 88%)
Chronic or intermittent PA status or ≥ 14 IV days 84% (83%, 86%) 83% (82%, 85%) 81% (79%, 82%) 79% (78%, 81%)
Abbreviations: IV, intravenous; PA, Pseudomonas aeruginosa; PPV, positive predictive value.
TABLE 3 Positive predictive value (PPV) for four different years' data in the prediction rule
Number of consecutive previous years
Predicted year; PPV (%)
2012 2013 2014 2015
1 year 94% (93%, 95%) 94% (93%, 95%) 94% (93%, 95%) 94% (94%, 95%)
2 years - 97% (96%, 97%) 96% (96%, 97%) 96% (95%, 97%)
3 years - - 97% (96%, 98%) 97% (96%, 98%)
4 years - - - 98% (97%, 98%)
F IGURE 2 Trade-off between PPV and number within the subset for each number of years' data (averaged across all years)
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successive years without an adjustment for patient characteristics
is sufficient.
Furthermore, the adjusted PPV at center level is very similar to
the unadjusted PPV, as shown in the funnel plot for 2015 (Figure 3).
The difference in the precision of the prediction is minimal, giving a
strong rationale that adjusting for covariates does not substantially
affect the accuracy of the predictions.
4 | DISCUSSION
Patients with positive PA samples can be accurately identified in
advance using routine data and a simple clinical rule. Patients with a
chronic PA status reported within the UK CF Registry for the previous
two consecutive years are likely to remain positive in the subsequent
year, with minimal variation between patients of differing presenting
characteristics or across treatment centers.
There are limitations to this work due to the data architecture of
the UK CF Registry. Firstly, if PA status is reported as “none,” this could
be because a person did not have PA infection, but alternatively may
arise by the patient not producing any sputum at clinic visits or by miss-
ing data. Secondly, advances in CF treatments, including treatments for
PA infection,18-20 means that the definition in this study should be re-
explored again with future registry data. Thirdly, although guidance on
the definition of chronic and intermittent P. aeruginosa status is provided
by the CF Registry, it is uncertain how closely this definition is followed
by individual CF centers. As encounter-based data are not available for
the data CF Registry dataset that was used, confirmation was not possi-
ble, and so an important next step will be to validate this rule against a
gold standard definition such as the Leeds criteria,21 a formally elicited
consultant judgment or a consensus definition.
Nevertheless, this prediction rule appears robust to differing patient
characteristics and may allow center comparisons to be carried out using
registry data. This is important, since center comparisons underpin
important advances in CF. For example, the comparisons of CF centers
TABLE 5 Regression model output
using the outcome of a patient having
positive PA samples within a given year
and patient characteristics as predictors
Variable
Model 1 (2013) Model 2 (2014) Model 3 (2015)
Coefficient (SE)
Age a* a* a
BMI 0.013 (0.047) 0.075 (0.039) 0.033 (0.042)
CF-related diabetes 0.730 (0.373) 0.717 (0.337)* 0.267 (0.283)
FEV1 (% pred) 0.279 (0.737) 0.888 (0.714) 0.219 (0.705)
IV days 0.006 (0.005) 0.002 (0.005) 0.012 (0.006)
Pancreatic insufficiency 0.365 (0.446) 0.017 (0.426) 0.841 (0.390)*
Female sex 0.017 (0.296) 0.450 (0.275) 0.062 (0.270)
IMD 0.009 (0.010) 0.002 (0.009) 0.010 (0.009)
Area under ROC curve 0.664 0.678 0.628
Note: *P < .05; **P < .01.
Abbreviations: BMI, body mass index; CF, cystic fibrosis; IMD, indices of multiple deprivation; IV,
intravenous; PA, Pseudomonas aeruginosa.
aAge was nonlinear with different functional forms: its effect on PPV plateaued after the age of 30 in all
cases.
TABLE 4 Contingency table
comparing the definition of two previous
years' chronic Pseudomonas aeruginosa
(PA) status (2011 and 2012) to predict a
patient having positive PA samples
within the current year (2013) compared
with a confirmed positive PA sample in
that year (2013)
Prediction year = 2013
Outcome
Positive samples No positive samples Total
Prediction Positive samples 1801 (97%) 60 (3%) 1861
No positive samples 811 (44%) 1038 (56%) 1849
Total 2612 1098 3710
F IGURE 3 Funnel plot for adjusted and unadjusted PPV by center
for 2013 predictions, lines reflect 95% (inner) and 99% (outer)
reference intervals
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in Toronto and Boston in the 1980s identifying the importance of
aggressive nutritional support22 is now a standard of care in CF.23
Due to the low prevalence of CF and the high numbers of
patients required to make comparisons based on key outcomes such
as FEV1,
24 process measures such as adherence are important in pro-
viding sensitive measures to identify differences in quality of care25
with higher adherence to treatments linked to better health out-
comes.26 The subgroup of people predicted to have PA in the current
year based on historic registry data provide a homogenous group in
whom to compare adherence rates with consensus about minimum
treatment regimens (mucolytic plus antibiotic), allowing a minimum
denominator to be imputed if prescription data are unavailable27-29).
Additionally, the use of convenience samples is a well-understood
limitation of comparing adherence between cohorts or centers.30 By
using this prediction rule to identify patients from a registry dataset
(more than 95% complete), researchers can understand to what
extent reported adherence data in a center has included all patients
with chronic PA. Identification of the number of patients included in
adherence rates within a center, compared with the numbers in the
historic registry data, allows an understanding of how many patients
are missing, thus illuminating the potential impact of sampling error
on estimates of center-level adherence. This work supports the
national indicator for CF patients31 that has been developed to use
adherence data from people with chronic PA to assess center-level
adherence and establish the missing patients within the center.
5 | CONCLUSION
The routine use of data-logging nebulizers in CF allows the number of
nebulizer doses used to be captured accurately at an individual level,
but there is uncertainty regarding the method to robustly compare
system-level adherence between different CF centers. The identifica-
tion of a subgroup of adults predicted to have PA infection using rou-
tine data provides a first step toward destination robust comparison
of system-level adherence between centers since there is consensus
regarding treatment targets in this subgroup. We have developed a
method of using routine data within the UK CF Registry to identify a
subgroup of adults who are predicted, with good accuracy, to have a
PA infection in the given year. The next step is to validate our method
against other definitions of chronic PA infection.
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APPENDIX
TABLE A1 Contingency table
comparing the definition of two previous
years' chronic PA status to predict a
patient having positive PA samples
within the current year (2014 and 2015
respectively) compared with a confirmed
positive PA sample in that year (2014
and 2015 respectively)
Prediction year = 2014
Outcome
Positive samples No positive samples Total
Prediction Positive samples 1804 (96%) 68 (4%) 1872
No positive samples 826 (41%) 1189 (59%) 2015
Total 2630 1257 3887
Prediction year = 2015
Outcome
Positive samples No positive samples Total
Prediction Positive samples 1782 (96%) 70 (4%) 1852
No positive samples 859 (39%) 1333 (61%) 2192
Total 2641 1403 4044
F IGURE A1 Funnel plot for adjusted and unadjusted PPV by
center for 2014 (top) and 2015 (bottom) predictions, lines reflect 95%
(inner) and 99% (outer) reference intervals
TABLE A2 Summary of CF center-level PPV, the number and
proportion of patients that are predicted to have positive PA samples




Median 98% 97% 97%
Min 85% 86% 86%
Max 100% 100% 100%
IQR 94%-99% 94%-100% 94%-99%
Number predicted to have positive PA samples
Median 49 53 52
Min 8 10 9
Max 273 279 249
IQR 27-82.5 22-82.5 19.5-76
Proportion predicted to have positive PA samples
Median 40% 37% 37%
Min 13% 8% 10%
Max 53% 55% 55%
IQR 32%-46% 31%-46% 28%-44%
Abbreviations: CF, cystic fibrosis; PA, Pseudomonas aeruginosa; PPV,
positive predictive value.
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